Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

25.50
+0.37001.47%
Post-market: 25.750.2500+0.98%17:03 EDT
Volume:731.36K
Turnover:18.57M
Market Cap:3.20B
PE:-7.75
High:25.91
Open:25.48
Low:24.58
Close:25.13
52wk High:28.72
52wk Low:7.06
Shares:125.35M
Float Shares:88.65M
Volume Ratio:0.30
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2900
EPS(LYR):-3.2900
ROE:-63.26%
ROA:-21.08%
PB:5.07
PE(LYR):-7.75

Loading ...

Arcus Biosciences grants new hire options for 4,200 shares, RSUs for 2,100 shares

Reuters
·
Yesterday

Arcus Biosciences rises 12.2%

TIPRANKS
·
Apr 22

Arcus Biosciences schedules conference call on quarterly results, pipeline update

Reuters
·
Apr 22

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

MT Newswires Live
·
Apr 22

Merck setback has positives and negatives for Arcus Biosciences, says BofA

TIPRANKS
·
Apr 22

Merck study miss not a read for Arcus, says H.C. Wainwright

TIPRANKS
·
Apr 22

Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Apr 21

Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Arcus Biosciences Discontinues Lung Cancer Trial With Gilead

Dow Jones
·
Apr 20

BRIEF-Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility

Reuters
·
Apr 20

Arcus Biosciences Inc - Gilead's Option Rights Under Collaboration Agreement to End July 14, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 20

Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due to Futility - SEC Filing

THOMSON REUTERS
·
Apr 20

Arcus Biosciences discontinues Phase 3 STAR-121 lung cancer trial for futility

Reuters
·
Apr 20

Arcus Biosciences grants new employee stock options for 7,850 shares under inducement plan

Reuters
·
Apr 10

Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List

TIPRANKS
·
Apr 02

Arcus Biosciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 02

Arcus Biosciences Inc : Wedbush Raises Target Price to $41 From $37

THOMSON REUTERS
·
Apr 02

Wedbush Raises Price Target on Arcus Biosciences to $41 From $37, Keeps Outperform Rating, Adds Stock to Best Ideas List

MT Newswires Live
·
Apr 02

Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound

Simply Wall St.
·
Mar 28